Procyclidine (Tricyclamol; (±)-Procyclidine) is an anticholinergic agent which is a muscarinic receptor antagonist as well as an N-methyl-D-aspartate ( NMDA ) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders, for example, Soman-induced epilepsy [1] [2].

Procyclidine (subcutaneous injection, 0.3-6.0 mg/kg) in combination with physostigmine (PhS) increases protection in a dose-dependent manner in rats and guinea pigs infected with soman and can prevent seizures altogether [1]. Animal Model: Male Sprague-Dawley rats, Dunkin-Hartley male guinea pigs [1] Dosage: 0.3-6.0 mg/kg Administration: Subcutaneous injection; once Result: Increased protection, resulting in 1.92, 2.24, 3.95 and 5.07 fold in rats, 3.00, 3.25, 4.50 and 4.70 fold in guinea pigs at the doses of 0.3, 1.0, 3.0 or 6.0 mg/kg, respectively. Protected the neurological integrity of the brain and prevented Soman-induced severe brain damage in the hippocampus, cortex, amygdala and thalamus.